TKIs in Philadelphia Chromosome-Positive ALL


For High-Definition, Click

The introduction of tyrosine kinase inhibitors (TKIs), like imatinib, for Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) has revolutionized outcomes in younger patients and created an opportunity for more definitive therapy in older individuals, according to Jeffrey Lancet, MD. Lancet notes that several smaller series of studies have demonstrated high response rates and significant disease-free survival rates in individuals who received TKIs with modified chemotherapeutic regimens or steroids.

Dan Douer, MD, and Mark R. Litzow, MD, agree that adults with Ph+ ALL should undergo allogeneic stem cell transplant following treatment with TKIs. In many instances, the level of response induced by targeted therapies lends itself to better outcomes from transplant. However, whether imatinib should be administered following transplantation remains an area of debate.

Related Videos
Lori A. Leslie, MD
Changchun Deng, MD, PhD
Guenther Koehne, MD, PhD
Ibrahim Aldoss, MD
Andrew P. Jallouk, BS, MD, PhD, assistant professor, Vanderbilt University
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Ibrahim Aldoss, MD
Kateryna Fedorov, MD, assistant professor, hematology-oncology, Vanderbilt University Medical Center
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Annie Im, MD, FASCO